Calls
1
u/Cubyface
Reddit r/biotech_stocks
Win Rate
-
return
-
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 15
$50.00
-
The author owns SRRK and believes it will be acquired by either LLY or NVO because of its muscle preservation function when used alongside GLP-1 drugs. The mechanism is strategic fit: GLP-1 makers may want to add a muscle-preserving agent to their obesity franchises, making SRRK an attractive acquisition target. No specific catalyst or timeframe is given, and the main risk is that no buyout materializes.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Cubyface has 1 trade ideas tracked on Buzzberg across 1 tickers since September 2026.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
